Recognan 100 mg / ml 10 ml , 10 pcs.

The oral solution is transparent, colorless, with a characteristic strawberry odor.

Excipients:

sorbitol - 20 g,

glycerol - 5 g,

methyl parahydroxybenzoate - 0.145 mg,

propyl parahydroxybenzoate - 0.025 mg,

potassium sorbate - 0.3 g,

sodium citrate dihydrate - 0.6 g,

sodium saccharinate - 0.02 g,

strawberry flavoring FRESA S.1487S - 0.04 g,

citric acid - up to pH 6.0,

purified water - up to 100 ml.

Clinical and pharmacological group:

Nootropic drug

Pharmaco-therapeutic group:

Nootropic agent

pharmachologic effect

Citicoline, being a precursor of key ultrastructural components of the cell membrane (mainly phospholipids), has a wide spectrum of action: it helps to restore damaged cell membranes, inhibits the action of phospholipases, preventing excessive formation of free radicals, and also preventing cell death by affecting the mechanisms of apoptosis.

In the acute period of stroke, it reduces the volume of damaged tissue, improves cholinergic transmission.

In traumatic brain injury, it reduces the duration of post-traumatic coma and the severity of neurological symptoms, in addition, it helps to reduce the duration of the recovery period.

Citicoline is effective in the treatment of cognitive, sensory and motor neurological disorders of degenerative and vascular etiology.

In chronic cerebral ischemia, citicoline is effective in the treatment of disorders such as memory impairment, lack of initiative, difficulties in performing daily activities and self-care. Increases the level of attention and consciousness, and also reduces the manifestation of amnesia.

Pharmacokinetics

Suction

Citicoline is well absorbed when taken orally. Absorption after oral administration is almost complete, and bioavailability is approximately the same as after intravenous administration. After oral administration and parenteral administration, the concentration of choline in the blood plasma increases significantly.

Distribution

Citicoline is largely distributed in the structures of the brain, with the rapid introduction of choline fractions into structural phospholipids and cytidine fractions - into cytidine nucleotides and nucleic acids. Citicoline enters the brain and is actively incorporated into the cell, cytoplasmic and mitochondrial membranes, forming part of the structural phospholipid fraction.

Metabolism

When administered intravenously and intramuscularly, citicoline is metabolized in the liver to form choline and cytidine.

Withdrawal

Only 15% of the administered dose of citicoline is excreted from the human body: less than 3% - by the kidneys and through the intestines and about 12% - with exhaled air.

In the excretion of citicoline in the urine, 2 phases can be distinguished: the first phase, lasting about 36 hours, during which the rate of excretion decreases rapidly, and the second phase, during which the rate of excretion decreases much more slowly. The same is observed in the exhaled air - the rate of excretion decreases rapidly after about 15 hours, and then decreases much more slowly.

- acute period of ischemic stroke (as part of complex therapy);

- the recovery period of ischemic and hemorrhagic strokes;

- traumatic brain injury (TBI), acute (as part of complex therapy) and recovery period;

- cognitive and behavioral disorders in degenerative and vascular diseases of the brain.

- vagotonia (predominance of the tone of the parasympathetic part of the autonomic nervous system);

- rare hereditary diseases associated with fructose intolerance (for oral administration);

- children and adolescents under 18 years of age (due to the lack of clinical data);

- hypersensitivity to drug components.

There is no information on relative contraindications for oral administration of the drug.

Frequency of adverse reactions: very rare (less than 1/10 000) (including isolated cases).

Allergic reactions: rash, pruritus, anaphylactic shock.

From the nervous system: headache, dizziness, insomnia, agitation, hallucinations. In some cases, the drug can stimulate the parasympathetic system, and also change blood pressure for a short time.

From the digestive system: nausea, vomiting, diarrhea, decreased appetite, changes in the activity of liver enzymes.

General reactions: feeling of heat, tremors, shortness of breath, numbness in paralyzed limbs, edema.

If any of these side effects are aggravated or any other side effects are noted, the patient should inform the doctor about it.

Citicoline enhances the effects of levodopa.

Should not be administered concomitantly with medicinal products containing meclofenoxate.

Oral solution

Take with meals or between meals. Before use, the drug can be diluted in a small amount of water (120 ml or 1/2 cup).

Acute period of ischemic stroke and TBI: 1000 mg (10 ml or 1 sachet) every 12 hours. Duration of treatment is at least 6 weeks.

The recovery period of ischemic and hemorrhagic strokes, the recovery period of TBI, cognitive and behavioral disorders in degenerative and vascular diseases of the brain: 500-2000 mg / day (5-10 ml 1-2 times / day or 1 sachet 1-2 times / day ). The dose and duration of treatment is set depending on the severity of the symptoms of the disease.

Elderly patients do not need dose adjustment.

Instructions for using the dosing pipette attached to the bottle

1. Place the dosing pipette into the vial (the piston of the pipette is completely lowered).

2. Gently pull the plunger of the dosing pipette until the solution level is level with the corresponding mark on the pipette.

3. Before taking the required amount of solution can be diluted in 1/2 glass of water (120 ml).

After each use, it is recommended to rinse the dosing pipette with water.

Recommendations for the use of the drug Recognan® in sachets

1. Take the 1000 mg Recognan® sachet by the edge and shake.

2. Tear off the edge of the bag at the dotted line.

3. Drink the contents of the packet immediately after opening.

4. Or dissolve in 1/2 glass of drinking water (120 ml) and drink.